<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04641936</url>
  </required_header>
  <id_info>
    <org_study_id>202010097RINC</org_study_id>
    <nct_id>NCT04641936</nct_id>
  </id_info>
  <brief_title>Urine Omics Predicting IO Therapy Responses in mUC Patients</brief_title>
  <official_title>Urine Metabolomics and Proteomics Profiling to Predict the Responses and Adverse Events of Immuno-Oncology-based Therapy in Patients With Metastatic Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to identify urinary metabolite and protein markers that can predict anti-tumor&#xD;
      efficacy and adverse events in subjects receiving IO-based therapies for metastatic&#xD;
      urothelial carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center single-arm translational study where patients with mUC who are about&#xD;
      to receive pre-determined IO-based anti-tumor therapy will be invited to participate the&#xD;
      study. After signing the approved informed consent, eligible and consenting subjects will&#xD;
      donate their fresh urine samples for subsequent untargeted metabolomics and proteomics study&#xD;
      via GS-MS/MS and/or LC-MS/MS to identify potential metabolite and protein markers that are&#xD;
      able to predict efficacy and side effects of IO-based therapies. All subjects in the&#xD;
      first-line, maintenance after 1st line, second-line, or subsequent lines of IO-based therapy&#xD;
      will be invited and recruited, but those who have received any IO-based therapy before the&#xD;
      study can NOT be recruited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event of special interest (AESI)</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Metastatic Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Validation cohort will be recruited in the next 36 months of the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention required</intervention_name>
    <description>No intervention required</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <biospec_descr>
    <textblock>
      fresh urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced and metastatic UC patients who will receive IO-based therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age &gt; 20 years&#xD;
&#xD;
          -  2. Subjects diagnosed as metastatic urothelial carcinoma (mUC)&#xD;
&#xD;
          -  3. Subjects who are about to receive IO-based therapy&#xD;
&#xD;
          -  4. ECOG performance 0, 1, 2, and 3&#xD;
&#xD;
          -  5. Life expectancy 3 months&#xD;
&#xD;
          -  6. eGFR &gt; 15 ml/min/1.73 m2 (Stage IV Chronic Kidney Disease or better)&#xD;
&#xD;
          -  7. Willing to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Subjects NOT willing to sign the informed consent form&#xD;
&#xD;
          -  2. Subjects with active infection or active urinary tract infection, as shown by&#xD;
             urinary WBC &gt; 5/HPF&#xD;
&#xD;
          -  3. Subjects having co-existing other malignancies that need active treatment. Those&#xD;
             with other malignancies that do not need active treatment are allowed to join the&#xD;
             study.&#xD;
&#xD;
          -  4. Subjects taking any immune-modulating agents, including but not limited to&#xD;
             corticosteroid, immune-suppressants, etc. at the discretion of recruiting&#xD;
             investigators&#xD;
&#xD;
          -  5. Subjects who have taken any CPIs before. However, subjects who have received&#xD;
             intravesical or intrapelvic BCG instillation are allowed to enroll.&#xD;
&#xD;
          -  6. Subjects who have received anti-FGFR therapy, enfortumab vedotin or other systemic&#xD;
             therapies within 12 weeks of screening are not allowed. However, subjects who had a&#xD;
             washout period of the above agents for &gt;12 weeks are allowed to enroll. Subjects who&#xD;
             have received or are receiving cytotoxic chemotherapy are allowed to join the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yeong Shiau Pu, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yeong Shiau Pu, MD PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65254</phone_ext>
    <email>pu5249@ntuh.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chung Hsin Chen, MD PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65242</phone_ext>
    <email>mufasachen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Yeong-Shiau Pu, MD PhD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65254</phone_ext>
      <email>pu5249@ntuh.gov.tw</email>
    </contact>
    <contact_backup>
      <last_name>Chung-Hsin Chen, MD PhD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65242</phone_ext>
      <email>mufasachen@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urothelial carcinoma</keyword>
  <keyword>biomarkers</keyword>
  <keyword>clinical responses</keyword>
  <keyword>IO-based therapies</keyword>
  <keyword>metabolomics</keyword>
  <keyword>proteomics</keyword>
  <keyword>Urine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

